Abstract:

Conventional treatment for advanced cervical cancer primarily consists of platinum-based concurrent chemoradiotherapy. However, this approach is associated with high rates of residual and recurrent disease, leading to poor prognosis. This report presents a case of advanced recurrent cervical cancer with renal failure. Treatment with cadonilimab combined with albumin-bound paclitaxel and bevacizumab resulted in partial response as evidenced by imaging, stable creatinine levels indicating well-preserved renal function, and a progression-free survival of 23 months. This case confirms the feasibility and safety of this combination regimen. For patients with advanced recurrent or metastatic cervical cancer, particularly those with renal impairment due to metastasis, conventional chemotherapy often shows limited efficacy and carries significant nephrotoxicity. Immune checkpoint inhibitors can enhance tumor regression rates, while bevacizumab combined with platinum-based chemotherapy has been shown to extend survival and exhibits lower renal toxicity, making it a key strategy in the treatment of advanced or metastatic cervical cancer. Therefore, for such patients, a strategy employing immune checkpoint inhibitors combined with bevacizumab, with conventional chemotherapeutic agents adjusted based on individual patients status, holds promise for prolonging survival.

Key words: Uterine cervical neoplasms, Carcinoma, Immunotherapy, Immune checkpoint inhibitors, Antibodies, bispecific, Cadonilimab